Abstract
The concept of prodromal chronic myeloproliferative neoplasms has been endorsed by the WHO classification implicating a stepwise evolution of disease. Histology of the bone marrow (BM) and borderline to mildly expressed clinical features play a pivotal role for diagnosing prefibrotic-early primary myelofibrosis. By lowering the platelet count for essential thrombocythemia and regarding BM morphology, early manifestations are tackled. Pre-polycythemic stages of polycythemia vera with a low hemoglobin level at onset are diagnosed by positive JAK2V617F mutation status, a low erythropoietin value, and characteristic BM features. The revised WHO classification incorporates hematological, morphological, and moleculargenetic parameters to generate a consensus-based working diagnosis. © 2009 Wiley-Liss, Inc.
Cite
CITATION STYLE
Kvasnicka, H. M., & Thiele, J. (2010, January). Prodromal myeloproliferative neoplasms: The 2008 WHO classification. American Journal of Hematology. https://doi.org/10.1002/ajh.21543
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.